Risk factors for venous and arterial thrombosis

Blood Transfusion

Volumn 9, Issue 2, 2011, Pages 120-138

  Previtali, Emanuele ^a   Bucciarelli, Paolo ^a   Passamonti, Serena M ^a   Martinelli, Ida ^a  

^a IRCSS General Hospital   (Italy)

Author keywords

Arterial thrombosis; Coagulation; Pathogenesis; Risk factors; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CLOPIDOGREL; DESOGESTREL; FIBRINOGEN; GESTODENE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; TAMOXIFEN; THIENOPYRIDINE DERIVATIVE;

AGE DISTRIBUTION; AIR POLLUTION; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTHROSCOPIC SURGERY; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; BREAST CANCER; CANCER RISK; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG INHIBITION; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; GENE MUTATION; HORMONAL THERAPY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMOBILIZATION; INJURY; LAPAROSCOPIC SURGERY; LUNG EMBOLISM; NONHUMAN; OBESITY; ORAL CONTRACEPTION; ORTHOPEDIC SURGERY; POSTTHROMBOSIS SYNDROME; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SMOKING; THROMBOPHILIA; THROMBOSIS; THROMBUS; TRAVEL; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; HUMANS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 79953700904     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.0066-10     Document Type: Review

References (175)

1. Hume M, Sevitt S, Thomas DP. Venous Thrombosis and Pulmonary Embolism. Harvard University Press, Cambridge, MA; 1970.
2. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart and legs. The Framingham Study. J Am Med Ass 1972; 221: 661.
3. th century. Am J Pub Health 1999; 89: 292-94.
4. Lowe GDO, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775-84. (Pubitemid 27321375)
5. Rumley A, Emberson JR, Wannamethee SG, et al. Effects of older age on fibrin D-dimer, C-reactive protein and other hemostatic and inflammatory variables in men aged 60-79 years. J Thromb Haemost 2006; 4: 982-7.
6. Abbate R, Prisco D, Rostagno C, et al. Age-related changes in the hemostatic system. Int J Clin Lab Res 1993; 23: 1-3.
7. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol 2006; 60: 144-151. (Pubitemid 44740495)
8. Coppola R, Mari D, Lattuada A, Franceschi C. von Willebrand factor in Italian centenarians. Haematologica 2003; 88: 39-43. (Pubitemid 36168853)
9. Kannell WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
10. Tracy RP. Hemostatic and inflammatory markers as risk factors for coronary disease in the elderly. Am J Geriatr Cardiol 2002; 11: 93-100.
11. Ofosu FA, Craven S, Dewar L, et al. Age-related changes in factor VII proteolysis in vivo. Br J Haematol 1996; 94: 407-12. (Pubitemid 26248004)
12. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-49.
13. Bauer KA, Weiss LM, Sparrow D, et al. Aging-associated changes in indices of thrombin generation and protein C activations in humans. Normative Aging Study. J Clin Invest 1987; 80: 1527-34. (Pubitemid 18007122)
14. Mari D, Mannucci PM, Coppola R, et al. Hypercoagulability in centenarians: the paradox of successful aging. Blood 1995; 85: 3144-9.
15. Wilkerson WR, Sane DC. Aging and thrombosis. Sem Thromb Hemost 2002; 28: 555-67. (Pubitemid 36026999)
16. Gleerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 1995; 46: 715-8.
17. Kasjanovova D, Balaz V. Age-related changes in human platelet function in vitro. Mech Ageing Dev 1986; 37: 175-82. (Pubitemid 17215488)
18. rd, Kadrofske MM, Vinik AI. Platelet activity and phosphoinositide turnover increase with advancing age. Am J Med 1990; 88: 601-6.
19. Taddei S, Virdis A, Ghiadoni L, et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 2001; 38: 274-9. (Pubitemid 34224757)
20. Feyzi E, Saldeen T, Larsson E, et al. Age-dependent modulation of heparan sulfate structure and function. J Biol Chem 1998; 273: 13395-8. (Pubitemid 28268375)
21. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31. (Pubitemid 32319498)
22. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106: 2605-12. (Pubitemid 41510730)
23. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7. (Pubitemid 24144355)
24. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8. (Pubitemid 23053939)
25. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703. (Pubitemid 26383091)
26. Ye Z, Liu EH, Higgings JP, et al. Seven hemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 1729-30.
27. Urbanus RT, Derksen RHMW, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev 2008; 22: 93-105. (Pubitemid 351282442)
28. Charakida M, Besler C, Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009; 302: 1210-7.
29. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76. (Pubitemid 29078298)
30. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11. (Pubitemid 27276540)
31. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109: 369-84. (Pubitemid 33064516)
32. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52. (Pubitemid 41532612)
33. Franchini M, Targher G, Montagnana M, et al. The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb Res 2008; 122: 727-35.
34. Prandoni P, Bilora F, Marchioli A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-41. (Pubitemid 36407172)
35. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004; 364: 937-52. (Pubitemid 39208455)
36. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
37. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
38. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519.
39. Wannamethee SG, Lowe GD, Shaper AG, et al. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 2005; 181: 101-8. (Pubitemid 40804699)
40. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003; 163: 2368-92. (Pubitemid 37310199)
41. Olufadi R, Byrne CD. Effects of VLDL and remnant particles on platelets. Pathophysiol Haemost Thromb 2006; 35: 281-91. (Pubitemid 44155946)
42. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-72. (Pubitemid 47090159)
43. Arteaga RB, Chirinos JA, Soriano AO, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006; 98: 70-4. (Pubitemid 43902682)
44. Becattini C, Agnelli G, Prandoni P, et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26: 77-83. (Pubitemid 40221127)
45. Prandoni P, Ghirarduzzi A, Prins MH, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006; 4: 1891-6. (Pubitemid 44226764)
46. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. J Am Med Ass 1997; 277: 642-5. (Pubitemid 27097428)
47. Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity. Risk factors for VTE among middle-aged men. "The study of men born in 1913". Arch Int Med 1999; 159: 1886-90.
48. Tsai A, Cushman M, Rosamond W, et al. Cardiovascular risk factors and VTE incidence. Arch Int Med 2002; 162: 1182-9.
49. Ageno W, Prandoni P, Romauldi E, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 4: 1914-8. (Pubitemid 44226768)
50. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102. (Pubitemid 350301144)
51. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008; 83: 97-102.
52. Vaya A, Mira Y, Ferrando F, et al. Hyperlipidemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002; 118: 255-9. (Pubitemid 34779546)
53. Deguchi H, Pecheniuk NM, Elias DJ, et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-9. (Pubitemid 41170077)
54. Ray J. Dyslipidemia, statins and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med 2003; 9: 378-84. (Pubitemid 36994065)
55. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-61.
56. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
57. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-45. (Pubitemid 44109954)
58. Pepine CJ. Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care. Ann Med 2010; 42: 19-35.
59. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-30. (Pubitemid 46631671)
60. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-16. (Pubitemid 46513296)
61. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43. (Pubitemid 351482735)
62. rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 1344-53.
63. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81. (Pubitemid 32179609)
64. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22. (Pubitemid 350146106)
65. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-8. (Pubitemid 351212675)
66. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16. (Pubitemid 46517957)
67. Prandoni P, Lensing AWA, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-60. (Pubitemid 35440241)
68. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: 122-30.
69. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-20.
70. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 2003; 25: 1-5. (Pubitemid 36527593)
71. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
72. Baglin T. What happens after venous thromboembolism? J Thromb Haemost 2009; 7: 287-90.
73. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071-4. (Pubitemid 37430448)
74. Palareti G, Cosmi B, Legnani C, et al, for the PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-9. (Pubitemid 44631361)
75. Rogers FB. Venous thromboembolism in trauma patients: a review. Surgery 2001; 130: 1-12.
76. Rocha AT, Tapson VF. Venous thromboembolism in intensive care patient. Clinical Chest Med 2003; 24: 103-22. (Pubitemid 36363142)
77. Abelseth G, Buckley RE, Pineo GE, et al. Incidence of DVT in patients with fractures of the lower extremity distal to the hip. J Orthop Trauma 1996; 10: 230-5. (Pubitemid 126432695)
78. van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous thrombosis. Arch Intern Med 2008; 168: 21-6.
79. Geerts WH, Pineo GP, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338-400S.
80. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90: 446-55. (Pubitemid 37138770)
81. Pineo GF, Hull RD. Prophylaxis of venous thromboembolism following orthopaedic surgery: mechanical and pharmacological approaches and the need for extended prophylaxis. Thromb Haemost 1999; 82: 918-24.
82. Ilahi OA, Reddy J, Ahmad I. Deep venous thrombosis after knee arthroscopy: a meta-analysis. Arthroscopy 2005; 21: 727-30. (Pubitemid 40779832)
83. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology (Am Soc Hematol Educ Program) 2005:1-12.
84. Arnout J, De Gaetano G, Hoylaerts M, et al. Thrombosis. Fundamental and Clinical Aspects. Leuven, Leuven University Press; 2003.
85. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 192-8. (Pubitemid 40053082)
86. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscl Thromb Vasc Biol 2004; 24: 1015-22. (Pubitemid 38737825)
87. Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol 2007; 137: 36-48. (Pubitemid 46426401)
88. Chirinos JA, Heresi GA, Velasquez H, et al. Elevation of endothelial microparticles, platelets and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005; 45: 1467-71. (Pubitemid 40615620)
89. Maugeri N, Brambilla M, Camera M, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost 2006; 4: 1323-1330.
90. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 9-12.
91. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701. (Pubitemid 40767088)
92. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: I17-I21. (Pubitemid 41289267)
93. Caine GJ, Stonelake PS, Lip GY, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4: 465-73. (Pubitemid 35417069)
94. Johnson MJ, Walker ID, Sproule MW, et al. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 1999; 21: 51-4. (Pubitemid 29143409)
95. Blom JW, Doggen CJM, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22. (Pubitemid 40216041)
96. Ambrus JL, Ambrus CM, Mink IB, et al. Causes of death in cancer patients. J Med 1975; 6: 61-4.
97. Kessler CM. The link between cancer and venous thromboembolism. Am J Clin Oncol 2009; 32: S3-S7.
98. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-10. (Pubitemid 40753746)
99. Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123. (Pubitemid 46242392)
100. nd ed. Oxford, UK: Wiley-Blackwell; 2009.
101. Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Control 2005; 12: 5-10. (Pubitemid 41356174)
102. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-505. (Pubitemid 350232226)
103. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalinomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-23. (Pubitemid 351255436)
104. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 1989; 320: 479-84. (Pubitemid 19062522)
105. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14: 2731-7. (Pubitemid 26329659)
106. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-83.
107. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164: 1965-76. (Pubitemid 39390552)
108. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1995; 346: 1575-82.
109. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93. (Pubitemid 26001840)
110. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6. (Pubitemid 26001841)
111. Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-8.
112. Farley TM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999; 5: 721-35. (Pubitemid 30034894)
113. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131-4. (Pubitemid 32678382)
114. Mammen EF. Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease. Hematol Oncol Clin North Am 2000; 14: 1045-59.
115. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202. (Pubitemid 29078302)
116. Almen T, Härtel M, Nylander G, et al. The effect of estrogen on the vascular endothelium and its possible relation to thrombosis. Surg Gynecol Obstet 1975; 140: 938-40.
117. Fawer R, Dettling A, Weihs D, et al. Effect of the menstrual cycle, oral contraception and pregnancy on forearm blood flow, venous distensibility and clotting factors. Eur J Clin Pharmacol 1978; 13: 251-7. (Pubitemid 8365530)
118. Godsland IF, Winkler U, Lidegaard Ø, et al. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs 2000; 60: 721-869.
119. Wynn V, Doear J, Mills G, et al. Fasting serum triglyceride, cholesterol, and lipoprotein levels during oral-contraceptive therapy. Lancet 1969; 2: 756-60.
120. Wynn V, Doear J, Mills G, et al. Some effects of oral contraceptives on serum-lipid and lipoprotein levels. Lancet 1966; 2: 720-3.
121. Kluft C, Lansink M. Effect of oral contraceptives on hemostasis variables. Thromb Haemost 1997; 78: 315-26. (Pubitemid 27289261)
122. Winkler UH. Blood coagulation and oral contraceptives: a critical review. Contraception 1998; 57: 203-9. (Pubitemid 29281906)
123. van Vliet HA, Bertina RM, Dahm AE, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008; 6: 346-51.
124. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999; 354: 2036-40.
125. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study in the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21. (Pubitemid 30433661)
126. Winkler UH. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 2000; 62: 11S-20S.
127. Tchaikovski SN, van Vliet HA, Thomassen MC, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost. 2007; 98: 1350-6. (Pubitemid 350239109)
128. Tan JY. Thrombophilia in pregnancy. Ann Acad Med Singapore 2002; 31: 328-34.
129. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 844S-886S.
130. Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632-637. (Pubitemid 351404930)
131. Ros HS, Lichtenstein P, Bellocco R, et al. Pulmonary embolism and stroke in relation to pregnancy: how can high-risk women be identified? Am J Obstet Gynecol 2002; 186: 198-203.
132. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-8. (Pubitemid 27464583)
133. Martinelli I, De Stefano V, Taioli E, et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87: 791-5. (Pubitemid 34516603)
134. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-80. (Pubitemid 30084535)
135. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77-85. (Pubitemid 36873862)
136. Gammaro L, Lippi G, Bottini E, et al. Severe preeclampsia in antithrombin III deficiency with no history of venous thromboembolism. J Nephrol 2001; 14: 312-5. (Pubitemid 32725284)
137. Brenner B. Thrombophilia and fetal loss. Semin Thromb Hemost 2003; 29: 165-70. (Pubitemid 36458195)
138. Rodger MA, Paidas M. Do thrombophilias cause placenta-mediated pregnancy complications? Semin Thromb Hemost 2007; 33: 597-603.
139. Rodger MA, Paidas M, McLintock C, et al. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 2008; 112: 320-4.
140. rd ed. Edinburgh, UK: Churchill Livingstone; 1994.
141. Brenner B. Hemostatic changes in pregnancy. Thromb Res 2004; 114: 409-14.
142. Clark P, Brennard J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-70. (Pubitemid 28297166)
143. Franchini M. Haemostasis and pregnancy. Thromb Haemost 2006; 95: 401-13.
144. Lockwood CJ, Krikun G, Runic R, et al. Progestin epidermal growth factor regulation of tissue factor expression during decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 2000; 85: 297-301. (Pubitemid 32268829)
145. Lanir N, Aharon A, Brenner B. Hemostatic mechanisms in human placenta. Best Pract Res Clin Haematol 2003; 16: 183-95.
146. Dalhamn T, Hellgren M, Blomback M. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecol Obstet Invest 1985; 20: 37-44. (Pubitemid 15015029)
147. WHO Working Group. Health Aspects of Air Pollution with Particulate Matter, Ozone and Nitrogen Dioxide. Accessed on 13/04/10 at http:/www.euro.who. int/air/activities/20050222-2).
148. Schwarze PE, Ovrevik J, Lag M, et al. Particulate matter properties and health effects: consistency of epidemiological and toxicological studies. Hum Exp Toxicol 2006; 25: 559-79. (Pubitemid 44804779)
149. Bathnagar A. Environmental cardiology. Studying mechanistic links between pollution and heart disease. Circ Res 2006; 99: 692-705.
150. Franchini M, Mannucci PM. Short-time effect of air pollution on cardiovascular diseases outcomes and mechanisms. J Thromb Haemost 2007; 5: 2169-74. (Pubitemid 47617866)
151. Brook RD, Franklin B, Cascio W, et al. Air pollution and cardiovascular disease. A statement for health case professionals from the expert panel on population and prevention science of the American Heart Association. Circulation 2004; 109: 2655-71.
152. Vermylen J, Nemmar A, Nemery B, et al. Ambient air pollution and acute myocardial infarction. J Thromb Haemost 2005;3:1955-1961. (Pubitemid 43086052)
153. Hoek G, Brunekreef B, Fischer P, et al. The association between air pollution and heart failure, arrhythmia, embolism, thrombosis, and other cardiovascular causes of death in a time series study. Epidemiology 2001; 12: 355-7.
154. Peters A, Dockery DW, Muller JE, et al. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 2001; 103: 2810-5.
155. Zanobetti A, Schwartz J. Air pollution and emergency admissions in Boston, MA. J Epidemiol Community Health 2006; 60: 890-5. (Pubitemid 44482810)
156. rd, Muhlestein JB, May HT, et al. Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. Circulation 2006; 114: 2443-8.
157. Lanki T, Pekkanen J, Aalto P, et al. Associations of traffic related air pollutants with hospitalisation for first acute myocardial infarction: the HEAPSS study. Occup Environ Med 2006; 63: 844-51. (Pubitemid 46024935)
158. Seaton A, Soutar A, Crawford V, et al. Particulate air pollution and the blood. Thorax 1999; 54: 1027-32. (Pubitemid 29495399)
159. Liao D, Heiss G, Chinchilli VM, et al. Association of criteria pollutants with plasma hemostatic/inflammatory markers: a population-based study. J Expo Anal Environ Epidemiol 2004; 15: 319-28.
160. Pekkanen J, Brunner EJ, Anderson HR, et al. Daily concentrations of air pollution and plasma fibrinogen in London. Occup Environ Med 2000; 57: 818-22.
161. Ruckerl R, Ibald-Mulli A, Koenig W, et al. Air pollution and markers of inflammation and coagulation in patients with coronary heart disease. Am J Respir Crit Care Med 2006; 173: 432-41. (Pubitemid 43228332)
162. Baccarelli A, Zanobetti A, Martinelli I, et al. Effects of exposure to air pollution on blood coagulation. J Thromb Haemost 2007;5:252-260. (Pubitemid 46139447)
163. Baccarelli A, Zanobetti A, Martinelli I, et al. Air pollution, smoking and plasma homocysteine. Environ Health Perspect 2007; 115: 176-81.
164. Baccarelli A, Martinelli I, Zanobetti A, et al. Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Int Med 2008; 168: 920-7. (Pubitemid 351679631)
165. Gallus AS. Travel, venous thromboembolism, and thrombophilia. Semin Thromb Hemost 2005; 31: 90-6. (Pubitemid 40262142)
166. Ten Wolde M, Kraaijenhagen RA, Schiereck J, et al. Travel and the risk of symptomatic venous thromboembolism. Thromb Haemost 2003; 89: 499-505. (Pubitemid 36329241)
167. Kuipers S, Schreijer AJM, Cannegieter SC, et al. Travel and venous thrombosis: a systematic review. J Intern Med 2007; 262: 615-34. (Pubitemid 350135194)
168. Cannegieter SC, Doggen CJM, van Houwelingen HC, et al. Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). PLoS Med 2006; 3: 1258-65. (Pubitemid 44338363)
169. Tardy B, Tardy-Poncet B, Bara L, et al. Effect of long travels in sitting position in elderly volunteers on biological markers of coagulation activation and fibrinolysis. Thromb Res 1996; 83: 153-60. (Pubitemid 26274433)
170. Colucci G, Stricker H, Roggiani W, at al. Venous stasis and thrombin generation. J Thromb Haemost 2004; 2: 1008-9.
171. Simons R, Krol J. Jet leg, pulmonary embolism, and hypoxia. Lancet 1996; 348: 416.
172. Hodkinson PD, Hunt BJ, Parmar K, et al. Is mild normobaric hypoxia a risk factor for venous thromboembolism? J Thromb Haemost 2003; 1: 2131-3.
173. Toff WD, Jones CI, Ford I, et al. Effect of hypobaric hypoxia, simulating conditions during long-haul air travel, on coagulation, fibrinolysis, platelet function, and endothelial activation. JAMA 2006; 295: 2251-61. (Pubitemid 43736575)
174. Schobersberger W, Schobersberger B, Mittermayr M, et al. Air travel, hypobaric hypoxia, and prothrombotic changes. JAMA 2006; 296: 2313-4. (Pubitemid 44749354)
175. Schreijer AJM, Cannegieter SC, Meijers JCM, et al. Activation of coagulation system during air travel: a crossover study. Lancet 2006; 367: 832-8. (Pubitemid 43363370)